The Incidence of RSV Infection Since the Introduction of Monoclonal Antibody Prophylaxis: An Analysis of Reported Case Data Across Germany for the Seasons 2023/24 and 2024/25.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

7 citing papers in PubMed.

1. [Otorhinolaryngologic infections in the post-pandemic context: What can we learn from the literature?]HNO · 2026
   Review
2. Burden of RSV-Associated Inpatient Care and Emergency Service Utilization in Two German Pediatric Centers Across Six Seasons Including the First Nirsevimab Year.Children (Basel, Switzerland) · 2026
   Article
3. Reduction in Respiratory Syncytial Virus (RSV)-Related Outpatient and Inpatient Cases Among Infants During the Initial 2024/2025 Season Following Nirsevimab Recommendation in Germany.Influenza and other respiratory viruses · 2026
   Article
4. Epidemiology of respiratory syncytial virus in a German hospital before, during and after the COVID-19 pandemic - a real world monocentric analysis over ten years.Frontiers in pediatrics · 2026
   Article
5. Changes in RSV-associated lower respiratory tract infections among hospitalized and outpatient children under 2 years in Northern Bavaria after general recommendation of Nirsevimab immunization in 2024.Infection · 2025
   Article
6. In Reply.Deutsches Arzteblatt international · 2025
   Article
7. Validity Is Limited.Deutsches Arzteblatt international · 2025
   Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

5 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.